Salute e Benessere

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine)…

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XRMost (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their...
Nasdaq GlobeNewswire
08/11/2025

Evaxion presents new immune data from phase 2 trial with AI-designed…

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data packageCOPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring...
Nasdaq GlobeNewswire
07/11/2025

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business…

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL:Lasme-cel in r/r B-ALL (BALLI-01)ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of...
Nasdaq GlobeNewswire
07/11/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
07/11/2025

Ipsen - October 2025 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 October 202583,814,526Gross total*...
Nasdaq GlobeNewswire
07/11/2025

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel…

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel“Cis-Demasking” Cytokine Technology to IncreaseTherapeutic Index of ImmunocytokinesNANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster on its novel OSE-Cytomask® Cis-Demasking 1immunocytokine technology at the Society for Immunotherapy...
Nasdaq GlobeNewswire
07/11/2025

IBA – Regulated information

November 7 th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total...
Nasdaq GlobeNewswire
07/11/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 7, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
07/11/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 10/31/2025100,325,45489,406,760For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
07/11/2025

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2025_48_Trading_By_Management
Nasdaq GlobeNewswire
07/11/2025

Preimplantation Genetic Testing Market worth $1,135.0 million by 2030 with 10.5%…

Browse in-depth TOC on "Preimplantation Genetic Testing Market" Browse in-depth TOC on "Preimplantation Genetic Testing Market" 200 - Tables45 - Figures300 - Pages By procedure type,the preimplantation genetic testing market is divided by procedure type into preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). This growth is primarily driven by the increasing use of PGS to detect chromosomal abnormalities before embryo transfer. End...
PR Newswire
07/11/2025

Virbac : Declaration of the number of shares and voting rights 10/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
07/11/2025

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302…

-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing--TK-6302 Clinical Trial Application planned in Q4 2025 for initiation of the Phase 1 ATLAS trial in 2026 SAN FRANCISCO and BERLIN, Nov.07, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced multiple...
Nasdaq GlobeNewswire
07/11/2025

2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb

Amid Sudan's devastating civil war and the near-total collapse of the country's health system, Dr. Eltaeb has kept Al Nao Hospital in Omdurman operating as one of the last functioning referral hospitals in greater Khartoum—a testament to his resilience and leadership under fire. AmidSudan'sdevastating civil war and the near-total collapse of the country's health system, Dr. Eltaeb has kept Al Nao Hospital in Omdurman operating as one of the last functioning referral hospitals in greater...
PR Newswire
07/11/2025

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting…

Interim data from the IQIRVO ®(elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, with a well-characterized safety profile over more than three years of treatment Additional new data from the ELATIVE trial highlights the potential for IQIRVO, a PPAR α/δ agonist, to beneficially impact fatigue-associated pathways linked to...
Nasdaq GlobeNewswire
07/11/2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Nov.07, 2025(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare...
Nasdaq GlobeNewswire
07/11/2025

Dr. Adrian Bot joins Immuthera to support the company with his unique experience…

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapiesDr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined Immuthera’s Board of Directors to strengthen its pipeline development and commercialization efforts.Immuthera, operating in the United States, is a wholly owned subsidiary of PolTREG S.A. a leader in innovative immune therapies with focus on regulatory T cell technologies...
Nasdaq GlobeNewswire
07/11/2025

Resolution Therapeutics announces new data showcasing the potential of…

First poster: Early modulation of liver function biomarkers INR and MELD is associated with positive long term clinical outcomes in patients with cirrhosis First poster: Early modulation of liver function biomarkers INR and MELD is associated with positive long term clinical outcomes in patients with cirrhosis DrPaul Brennan, Clinical Lecturer in Hepatology at theUniversity of Dundee, UK, will present a poster titled " Early modulation of INR and MELD after regenerative macrophage...
PR Newswire
07/11/2025

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all…

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years and older compared to placeboDupixent sBLA accepted for priority review by the US FDA with a...
Nasdaq GlobeNewswire
07/11/2025

Notification of managers’ transactions

ANNOUNCEMENT NO. 298 7 November 2025Notification of managers’ transactionsChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Kim Nicolajsen in the attached PDF document.For further information, please contact:Kim Nicolajsen, CFO...
Nasdaq GlobeNewswire
07/11/2025

Notification of managers’ transactions

ANNOUNCEMENT NO. 297 7 November 2025Notification of managers’ transactionsChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CEO Martin Helbo Behrens in the attached PDF document.For further information, please contact:Kim Nicolajsen,...
Nasdaq GlobeNewswire
07/11/2025

138th Canton Fair: China's Apparel Industry Threads a New Path with Innovation…

Innovation in functional design also took center stage. A manufacturer from Jilin introduced heated apparel incorporating built-in electric elements to provide active warmth for cold environments. This product has already gained strong traction in the U.S. market. The company's cooling garments, designed with advanced ventilation components, offer comfort in hot climates and are gradually expanding into European and American markets. The company's fashion-forward workwear line, which merges…
PR Newswire
07/11/2025

Black November Surge: Flooring365.co.uk Responds to Seasonal Renovation Boom…

As winter renovations continue to trend upwards, particularly in the run-up to Christmas, this extended sale aims to help homeowners upgrade their floors with quality materials—without the usual price tag. As winter renovations continue to trend upwards, particularly in the run-up to Christmas, this extended sale aims to help homeowners upgrade their floors with quality materials—without the usual price tag. "November is always a key time for renovations, and we know people are keen to...
PR Newswire
07/11/2025

Major shareholder announcement

Please read the full announcement in PDFAttachments 2025_47_Major_Shareholders_AnnouncementNovozymes B 05 November 2025_Final
Nasdaq GlobeNewswire
07/11/2025
Altri  Comunicati